DarioHealth's analyst price target has been revised downward from $25.50 to $22.25. This reflects analysts' updated outlook based on lower fair value estimates and a slightly reduced discount rate.
What's in the News
- DarioHealth's Board of Directors has launched a comprehensive strategic review to explore options such as a sale, merger, business combination, or continuing as a standalone company, following multiple unsolicited strategic inquiries (Key Developments).
- The company closed a private placement on September 23, 2025 (Key Developments).
- DarioHealth entered into securities purchase agreements and completed the sale of over 1.15 million common shares and 1.55 million pre-funded warrants, raising gross proceeds of $17.5 million on September 22, 2025 (Key Developments).
- Five new contracts went live with self-insured employers, featuring Dario's full cardiometabolic suite. This highlights demand for integrated, multi-condition solutions (Key Developments).
- A 1-for-20 stock split or significant stock dividend was completed on August 28, 2025 (Key Developments).
Valuation Changes
- Fair Value Estimate has decreased from $25.50 to $22.25, reflecting a lower assessment.
- Discount Rate has been reduced from 12.32% to approximately 9.88%, indicating a lower perceived risk.
- Revenue Growth projection remains nearly unchanged at around 18.28%.
- Net Profit Margin estimate is effectively stable, moving from 8.77% to 8.77%.
- Future P/E ratio has declined from 18.35x to 14.99x, which suggests a less aggressive valuation outlook.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.